Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2022-02-07 Call Transcript
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform you that subsequent to the declaration of unaudited ....
Call Transcript Classification · 90% confidence The document is an intimation to stock exchanges about a scheduled conference call following the announcement of unaudited financial results for the third quarter ended December 31, 2021. It references the Q3 FY 2022 results announcement and provides details for an investor/analyst conference call to discuss these results. The document does not contain the financial results themselves, nor detailed financial statements or analysis. It is essentially a notification of a conference call event related to earnings results, not the earnings release or the transcript of the call. Therefore, it fits best as a Call Transcript (CT) precursor or announcement. However, since it is only an announcement of the conference call and not the transcript, the closest fitting category is Call Transcript (CT) because the document is about the conference call related to earnings results. Confidence is high given the clear references to the conference call and Q3 results.
2022-02-07 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an intimation to stock exchanges about an upcoming conference call to discuss the financial results for the third quarter ended December 31, 2021. It references the declaration of unaudited standalone and consolidated financial results for Q3 FY 2021-2022 and provides details for an investor and analyst conference call scheduled after the results announcement. The document does not contain the financial results themselves, nor detailed financial statements or analysis. It is a notification about the conference call event related to the earnings release, not the earnings release itself or a transcript. Therefore, the document is best classified as a Regulatory Filing (RNS) because it is an official regulatory announcement informing the market about the conference call following the earnings announcement, but it is not the earnings release or call transcript itself.
2022-02-07 English
Loss of Share Certificates
Regulatory Filings
2022-01-20 English
Pursuant to the Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find attached herewith ....
Regulatory Filings
2022-01-20 English
Board Meeting — Financial Results/Other business matters
Board/Management Information Classification · 95% confidence The document is a notice of an upcoming Board Meeting scheduled for February 8, 2022. It mentions the agenda items including approval of un-audited financial results for the quarter ended December 31, 2021, and a proposal regarding preference shareholders' rights and share conversion. The document is a formal intimation to stock exchanges as per SEBI regulations. It does not contain actual financial results or detailed reports but is an announcement of a board meeting and its agenda. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report or financial statement itself.
2022-01-20 English
MOREPEN LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2022 ,inter alia, to consider and approve (1) Standalone and consolidated ....
Regulatory Filings Classification · 95% confidence The document is a notice of a scheduled Board Meeting of Morepen Laboratories Limited. It mentions the agenda items including approval of un-audited financial results for the quarter ended December 31, 2021, and a proposal regarding preference shareholders' rights and share issuance. The document is short (1969 characters) and serves as an intimation or announcement of the upcoming board meeting and its agenda, not the actual financial results or detailed report. It is a regulatory announcement related to board activities but does not announce changes in board members or senior management. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and notice of board meeting under SEBI regulations.
2022-01-20 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.